Durvalumab: beside a new treatment under test

248 studies: a new drug, cell therapy or vaccine is what the study tests. Page 2 of 3. Open to participants first (57), then studies with results posted, then the rest; newest registration first within each.

• A Study of LY2510924 and Durvalumab in Participants With Solid TumorsTerminatedNCT02737072Phase 1Results postedReport a problem
• A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid TumorsCompletedNCT02718911Phase 1Results postedReport a problem
• A Study of Durvalumab (MEDI4736) and Monalizumab in Solid TumorsActive, not recruitingNCT02671435Phase 1/2Results postedReport a problem
• Brain Irradiation and Tremelimumab in Metastatic Breast CancerCompletedNCT02563925Not applicableResults postedReport a problem
• Study of Tremelimumab in Patients With Advanced Solid TumorsCompletedNCT02527434Phase 2Results postedReport a problem
• Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & NeckCompletedNCT02499328Phase 1/2Results postedReport a problem
• A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203)CompletedNCT02318277Phase 1/2Results postedReport a problem
• Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic SyndromesCompletedNCT02281084Phase 2Results postedReport a problem
• A Phase 1b/2 Safety and Tolerability Study of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal AntibodiesTerminatedNCT02205333Phase 1/2Results postedReport a problem
• A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced MalignanciesCompletedNCT02118337Phase 1/2Results postedReport a problem
• Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )TerminatedNCT06939036Phase 1/2Report a problem
• Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)Active, not recruitingNCT06898957Phase 1Report a problem
• Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung CancerActive, not recruitingNCT06732401Phase 3Report a problem
• Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and TremelimumabActive, not recruitingNCT06710223Phase 1Report a problem
• Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)SuspendedNCT06694454Phase 1/2Report a problem
• BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular CarcinomaWithdrawnNCT06608940Phase 1/2Report a problem
• A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung Cancer (LADOGA)Active, not recruitingNCT06606847Phase 2Report a problem
• Phase II Study of Durvalumab(MEDI4736) + Tremelimumab in Pulmonary Sarcomatoid CarcinomaCompletedNCT06446570Phase 2Report a problem
• Trial of INI-4001 in Patients With Advanced Solid TumoursCompletedNCT06302426Phase 1Report a problem
• Study of Imdusiran (AB-729) in Combination With Intermittent Dosing of Durvalumab in Subjects With Chronic HBV InfectionWithdrawnNCT06245291Phase 2Report a problem
• A Phase I Trial of IMA970A Plus Montanide in Combination With Durvalumab (Anti-PD-L1)Active, not recruitingNCT06218511Phase 1Report a problem
• A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast CancerActive, not recruitingNCT06112379Phase 3Report a problem
• DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)Active, not recruitingNCT06027086Phase 1/2Report a problem
• A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based ChemotherapyActive, not recruitingNCT05941897Phase 2Report a problem
• Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for Therapy EfficacyActive, not recruitingNCT05927142Phase 1/2Report a problem
• Abequolixron (RGX-104) and Durvalumab in Lung CancerTerminatedNCT05911308Phase 1Report a problem
• Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic AlterationsActive, not recruitingNCT05687266Phase 3Report a problem
• A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid TumoursActive, not recruitingNCT05514132Phase 1Report a problem
• A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based ChemotherapyActive, not recruitingNCT05450692Phase 3Report a problem
• Randomized Phase II, Open-label Efficacy and Safety Study of Second-line Durvalumab Plus Tremelimumab Versus Platinum-based Chemotherapy Alone in Patients With NSCLC and First-line Checkpoint-inhibitor Therapy (Re-Check)WithdrawnNCT05383001Phase 2Report a problem
• Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLCActive, not recruitingNCT05374603Phase 2Report a problem
• First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)Active, not recruitingNCT05361395Phase 1Report a problem
• A Trial of AN0025 With Chemoradiation Therapy in Stage III NSCLC ParticipantsWithdrawnNCT05358691Phase 1Report a problem
• Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCCActive, not recruitingNCT05301842Phase 3Report a problem
• A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung CancerActive, not recruitingNCT05221840Phase 3Report a problem
• A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLCActive, not recruitingNCT05211895Phase 3Report a problem
• Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung CancerActive, not recruitingNCT05198830Phase 2Report a problem
• Trial of Local Cystoscopic Injection of Tremelimumab Plus Systemic Durvalumab for High Risk Non-Muscle Invasive Bladder CancerWithdrawnNCT05120622Phase 1/2Report a problem
• Gut Microbiota Reconstruction for NSCLC ImmunotherapyStatus unknownNCT05008861Phase 1Report a problem
• Concomitant Radiotherapy, Tremelimumab & Durvalumab for Advanced NSCLC Patients Progressing on First-line ImmunotherapyActive, not recruitingNCT05000710Phase 2Report a problem
• TACE and SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular CarcinomaActive, not recruitingNCT04988945Phase 2Report a problem
• To Evaluate the Efficacy of Durvalumab + Anlotinib in Terms of OS and PFS.Active, not recruitingNCT04985851Not applicableReport a problem
• Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic CancerActive, not recruitingNCT04940286Phase 2Report a problem
• Vactosertib and Durvalumab in Gastric CancerStatus unknownNCT04893252Phase 2Report a problem
• TremelImumab aNd Durvalumab For the Non-operatIve Management (NOM) of MSI-high Resectable GC/GEJC.Active, not recruitingNCT04817826Phase 2Report a problem
• Combination of Durvalumab and BVAC-C in Patients With HPV 16 or 18 Positive Cervical Cancer Failure to First-Line Platinum-based ChemotherapyStatus unknownNCT04800978Phase 2Report a problem
• Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung CancerActive, not recruitingNCT04699838Phase 2Report a problem
• The Efficacy and Safety of CKD516 Combined With Durvalumab in Patient Refractory Solid TumorsTerminatedNCT04696848Phase 1/2Report a problem
• Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic SarcomaActive, not recruitingNCT04668300Phase 2Report a problem
• A Study of MEDI9253 in Combination With Durvalumab in Select Solid TumorsTerminatedNCT04613492Phase 1Report a problem
• Rh-Endostatin Combined With CCRT(50 Gy) Followed by Durvalumab Maintenance for the Treatment of Specific Phase III NSCLCStatus unknownNCT04613284Phase 4Report a problem
• Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung CancerActive, not recruitingNCT04612751Phase 1Report a problem
• Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver CancerActive, not recruitingNCT04605731Phase 1Report a problem
• AZD2811 and Durvalumab (MEDI4736) Combination Therapy in Relapsed Small Cell Lung CancerTerminatedNCT04525391Phase 2Report a problem
• Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCCActive, not recruitingNCT04522544Phase 2Report a problem
• Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 MutationsActive, not recruitingNCT04521686Phase 1Report a problem
• First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid TumoursCompletedNCT04504669Phase 1Report a problem
• Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung CancerActive, not recruitingNCT04397003Phase 2Report a problem
• Durvalumab(MEDI4736) and AZD6738 Combination Therapy in Relapsed Small Cell Lung Cancer SubjectsCompletedNCT04361825Phase 2Report a problem
• DDR-Umbrella Study of DDR Targeting Agents in Advanced Biliary Tract CancerActive, not recruitingNCT04298021Phase 2Report a problem
• Assess the Safety of Immunotherapy Induction With Tremelimumab and Durvalumab Prior to Chemoradiotherapy and/or Resection in the TreatmentTerminatedNCT04287894Phase 1Report a problem
• A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Pancreatic Adenocarcinoma, Non-Small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck to Correlate Clinical, Molecular and Immunologic Parameters With DNA MethylationWithdrawnNCT04262388Phase 2Report a problem
• A Phase 2 Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Multi-Cancer Populations With Correlation to Clinical, Molecular and Immunologic Parameters With DNA MethylaTIONWithdrawnNCT04262375Phase 2Report a problem
• IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors.CompletedNCT04261075Phase 1Report a problem
• Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal CancerWithdrawnNCT04231864Phase 2Report a problem
• Programmed Cell Death 1 + Selected Cell Therapy With Durvalumab (MEDI4736) and Tremelimumab in Metastatic MelanomaWithdrawnNCT04223648Early Phase 1Report a problem
• Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib TreatmentActive, not recruitingNCT04169841Phase 2Report a problem
• Progression-free Survival After MWA Plus Durvalumab and Tremelimumab for Unresectable Locally Advanced Pancreatic CancerCompletedNCT04156087Phase 2Report a problem
• TRIO Bladder: A Study of Durvalumab Plus Tremelimumab Followed by Concurrent Durvalumab Plus Bladder Radiation in Muscle-Invasive Bladder CancerWithdrawnNCT04073160Phase 1Report a problem
• ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no LossActive, not recruitingNCT04065269Phase 2Report a problem
• Vactosertib with Durvalumab in Urothelial Carcinoma Failing Checkpoint InhibitionWithdrawnNCT04064190Phase 2Report a problem
• Non Small Cell Lung Cancer Trial of Durvalumab and Tremelimumab in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Disease.Status unknownNCT03994393Phase 2Report a problem
• Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.Active, not recruitingNCT03983954Phase 1Report a problem
• Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid TumorsWithdrawnNCT03982173Phase 2Report a problem
• A Study of MEDI1191 in Sequential and Concurrent Combination With Durvalumab in Subjects With Advanced Solid TumorsCompletedNCT03946800Phase 1Report a problem
• Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract CarcinomaActive, not recruitingNCT03937830Phase 2Report a problem
• Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung CancerActive, not recruitingNCT03923270Phase 1Report a problem
• Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid TumorsCompletedNCT03911557Phase 2Report a problem
• A Phase II Study of Neoadjuvant Chemotherapy Plus Durvalumab (MEDI4736) and Tremelimumab in Advanced-stage Ovarian Cancer (TRU-D)Status unknownNCT03899610Phase 2Report a problem
• A Study of MEDI5395 in Combination With Durvalumab in Participants With Select Advanced Solid TumorsCompletedNCT03889275Phase 1Report a problem
• Improve Checkpoint-blockade Response in Advanced Urothelial CancerCompletedNCT03871036Phase 1/2Report a problem
• Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI ResistanceActive, not recruitingNCT03833440Phase 2Report a problem
• Safety,Tolerability,and Efficacy of VCN-01 With Durvalumab in R/M Head and Neck Squamous Cell CarcinomaStatus unknownNCT03799744Phase 1Report a problem
• GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel StudyCompletedNCT03751761Phase 1/2Report a problem
• Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced MalignanciesCompletedNCT03739931Phase 1Report a problem
• Phase 1b/2a, Open-label Study of Vactosertib in Combination With Durvalumab in Advanced NSCLCCompletedNCT03732274Phase 1/2Report a problem
• Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1TerminatedNCT03721679Phase 1/2Report a problem
• Durvalumab + Tremelimumab ± Paclitaxel in Advanced BTC After Platinum Chemotherapy.Active, not recruitingNCT03704480Phase 2Report a problem
• Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid TumorsActive, not recruitingNCT03682289Phase 2Report a problem
• IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid TumorsTerminatedNCT03665129Phase 1Report a problem
• Paclitaxel + Carboplatin + Durvalumab With or Without Oleclumab for Previously Untreated Locally Recurrent Inoperable or Metastatic TNBCActive, not recruitingNCT03616886Phase 1/2Report a problem
• Durvalumab (MEDI4736) and Tremelimumab in Hormone Receptor-positive, Hypermutated Metastatic Breast Cancer Identified by Whole Exome SequencingCompletedNCT03608865Phase 2Report a problem
• PolyImmune {Durvalumab (MEDI4736) and Tremelimumab} & Vaccine Orchestrated Treatment for Patients With Advanced/Metastatic Renal Cell CarcinomaWithdrawnNCT03598816Phase 2Report a problem
• Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.Status unknownNCT03544723Phase 2Report a problem
• Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid TumoursCompletedNCT03518606Phase 1/2Report a problem
• Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract CancerActive, not recruitingNCT03482102Phase 2Report a problem
• Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine/Cisplatin Compared to Gemcitabine/Cisplatin in CCA PatientsCompletedNCT03473574Phase 2Report a problem
• Durvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients (DUTRENEO)CompletedNCT03472274Phase 2Report a problem
• Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar CancersCompletedNCT03452332Phase 1Report a problem
• Durvalumab Plus Tremelimumab Combined With Proton Therapy for HNSCCStatus unknownNCT03450967Phase 2Report a problem

← Durvalumab